Pinnacle Medicines, an oral peptide startup, raised $89 million in a Series B backed by U.S. and China investors, following OrbiMed’s involvement. The round brings Pinnacle’s total fundraising to $134 million, positioning it to scale its oral peptide pipeline after early investor interest in how peptide chemistry could be translated into pill formats. The company’s valuation strategy is tied to the continued market pull for oral alternatives to injectable GLP-1–like assets and other peptide-derived therapies, although Pinnacle’s near-term output will hinge on whether its lead programs show consistent potency, stability, and tolerability in clinical settings. This funding also signals that investors are willing to place large bets on delivery and formulation know-how, not just target biology. For biotech operators, the Pinnacle raise is a reminder that peptide modality engineering remains capital-intensive, and scale-up funding can be decisive for advancing candidates toward IND-enabling packages and early clinical proof.